Johnson & Johnson / Tibotec-Virco NV

HIV/AIDS (Drug-Resistant Strains)

32K US cases/yr

Disease Overview

HIV is a chronic retroviral infection that, untreated, progresses to AIDS via CD4+ T-cell depletion. By 2002, combination antiretroviral therapy had transformed HIV into a manageable chronic disease, but resistance to first-generation NNRTIs and protease inhibitors was emerging as the dominant unmet need, particularly among heavily treatment-experienced patients.

Competitive Landscape

The 2002 J&J acquisition of Tibotec-Virco for $320M positioned the buyer as a serious antiviral player at a time when the HIV market was dominated by GlaxoSmithKline (Combivir, Trizivir), Bristol-Myers Squibb (Sustiva, Reyataz), Merck (Crixivan, Stocrin), and Abbott (Kaletra, Norvir). Tibotec brought two next-generation HIV pipeline assets specifically optimized against drug-resistant strains: TMC114 (later darunavir/Prezista, FDA-approved 2006) — a non-peptidic protease inhibitor with high genetic barrier to resistance — and TMC125 (later etravirine/Intelence, FDA-approved 2008) — a second-generation NNRTI active against K103N-resistant virus. Virco's VirtualPhenotype HIV resistance-testing service (>120,000 genotypes/phenotypes) became a strategic data asset informing both clinical practice and J&J's own pipeline. Post-acquisition, Tibotec was rebranded Janssen Therapeutics in 2011 and went on to develop bedaquiline (Sirturo, first new TB drug in 40 years) and simeprevir (Olysio) for HCV — making the deal one of the most productive antiviral acquisitions of the 2000s relative to its $320M price tag.